Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor necrosis factor
(
TNF
), a macrophage product released in response to endotoxin and other stimuli, has been shown to be a central mediator of endotoxin or septic shock. However, its highly conserved and wide-ranging physiological effects suggest that it may also be an essential cytokine in the host defense against acute bacterial infection or sepsis. A single nontoxic dose of human recombinant
TNF
administered intravenously 24 h prior to a lethal infusion of Escherichia coli
lipopolysaccharide
(
LPS
) completely prevented acute
LPS
-induced hypotension, ameliorated tissue injury in the lungs and liver, and improved survival in male Fisher 344 rats. The protective effects of
TNF
were dose dependent and required a 24-h pretreatment interval. After the infusion of
LPS
, animals in both groups (
TNF
-treated animals and saline-pretreated controls) initially appeared acutely ill and had a similar severe metabolic acidosis, indicating that
TNF
did not inactivate or prevent the toxic effects of
LPS
. Twelve hours after the administration of
TNF
, the gene for manganous superoxide dismutase, a mitochondrial enzyme which scavenges toxic reactive oxygen species and is induced during conditions which generate a free radical stress, was expressed in liver tissue, suggesting that the induction of manganous superoxide dismutase may be an important in vivo protective mechanism against cellular injury during lethal endotoxemia.
...
PMID:Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. 193 48
Tumor necrosis factor
(
TNF
) has significant biologic effects. Inhibitors of
TNF
have been isolated from urine and blood. We studied pleural fluid from 22 patients with benign or malignant effusions. Pleural macrophages from these effusions were capable of releasing
TNF
, especially when stimulated with
lipopolysaccharide
. The cell-free supernatant from some of these pleural effusions contained an inhibitor of
TNF
. Fluid from 12 malignant effusions contained an inhibitor of 17% +/- 15.4% (mean +/- SD) of 500 U/ml of
TNF
activity, whereas the mean inhibition in 10 benign effusions was 2% +/- 5.6% (p less than 0.05). Only one of 10 benign effusions had more than 10% inhibitory activity. This inhibitor was found to be heat sensitive and unaffected by dialysis, and the molecular weight of at least one of the inhibitors was 60 to 80,000 daltons. Enzyme digestion studies were consistent with a protein portion being the major determinant of activity. We conclude that some malignant effusions contain an inhibitor of
TNF
activity.
...
PMID:An inhibitor of tumor necrosis factor found in pleural effusions. 194 May 74
Tumor necrosis factor
(
TNF
) is a macrophage derived peptide that has an antitumor action and modulates immune and inflammatory reactions. Dietary fatty acids may modulate
TNF
production as dietary n-3 polyunsaturated fatty acids suppress human monocyte
TNF
production, but enhance its secretion by murine peritoneal macrophages. Mice were maintained for 5 weeks on diets containing different amounts of n-3 and n-6 fatty acids.
TNF
, PGE2 and 6-keto PGF1 alpha production was monitored following in vitro stimulation of resident peritoneal macrophages with
lipopolysaccharide
. Macrophages from mice fed the high n-3 diet produced 8-fold more
TNF
and half the PGE2 produced by macrophages from mice on the other diets. Indomethacin caused an increase in the
TNF
production by macrophages from mice on all diets but macrophages from mice on the high n-3 diet produced more
TNF
than macrophages from mice on the other diets. Exogenous PGE2 (100 nM) greatly decreased
TNF
production by macrophages from mice on all diets, but macrophages from mice on the high n-3 diet secreted 70% more
TNF
than macrophages from mice fed the other diets, indicating that PGE2 is only partly responsible for the effects observed. The results show that feeding n-3 polyunsaturated fatty acids may cause enhanced
TNF
production by resident peritoneal macrophages and that PGE2 is partly responsible for the effect.
...
PMID:Tumor necrosis factor production by murine resident peritoneal macrophages is enhanced by dietary n-3 polyunsaturated fatty acids. 195 93
Tumor necrosis factor
(
TNF
) is a cytokine which mediates endotoxin shock and causes multiple organ damage. It is thought that macrophage (MP) activation is necessary to increase
lipopolysaccharide
(
LPS
)-induced
TNF
production and lethality. Carrageenan (CAR) is sulfated polygalactose which destroys MP; it is used as a MP blocker. We found that CAR pretreatment can increase both endotoxin-induced
TNF
production and the mortality rate in mice. The ddY mice (7 to 8 weeks old) were injected intraperitoneally with CAR (5-mg dose) and challenged intravenously with
LPS
24 h later. Without CAR pretreatment,
LPS
doses of less than 10 micrograms did not induce
TNF
in sera. After pretreatment, however, about 3 x 10(3) to 4 x 10(4) U of
TNF
per ml was produced after
LPS
injection at doses of 0.1 to 10 micrograms, respectively.
TNF
production was significantly increased by CAR pretreatment at
LPS
doses of more than 10 micrograms. CAR pretreatment rendered the mice more sensitive to the lethal effect of
LPS
; 50% lethal doses of
LPS
in CAR-pretreated mice and nonpretreated mice were 26.9 and 227 micrograms, respectively. The mortality of the two groups was significantly different at doses of 50, 100, and 200 micrograms of
LPS
. CAR increased
LPS
-induced
TNF
production and mortality within 2 h, much earlier than MP activators, which needed at least 4 days. Our results made clear that
TNF
production is enhanced not only by a MP activator but also by a MP blocker.
...
PMID:Enhancement of lipopolysaccharide-induced tumor necrosis factor production in mice by carrageenan pretreatment. 198 84
Using a model of sepsis induced by parenteral challenge of mice with bacterial
lipopolysaccharide
(
LPS
), the authors analyzed the in vivo expression of interleukin-1 (IL-1) alpha,beta and tumor necrosis factor (TNF). Both TNF and IL-1 alpha,beta were detected in hepatic sinusoidal macrophages (Kupffer cells), immunohistochemically. Kinetic analysis showed a clear sequence of synthesis.
Tumor necrosis factor
was produced first, reaching maximal expression at 1 hour after
LPS
challenge, then rapidly disappeared. IL-1 beta followed, reaching maximal expression at 2 to 3 hours, then dropped off by 6 hours. Interleukin-1 alpha expression reached a peak at 6 hours and had disappeared by 18 hours. Analysis of serum bioactivity also revealed sequential expression that correlated with immunohistochemical findings.
Tumor necrosis factor
was maximal at 1 hour and IL-1 at 6 hours. The IL-1 bioactivity was not due to interleukin-6 (IL-6), as this was depleted from specimens by immunoabsorption. Also IL-6 bioactivity reached maximal levels at 3 hours, earlier than IL-1. Pretreatment with 4 mg/kg dexamethasone significantly decreased Kupffer cell expression of TNF and IL-1 alpha (about 80% and 60% suppression, respectively) but had less effect on IL-1 beta expression (about 30% suppression). Accordingly, serum levels of TNF were suppressed by 75% while serum IL-1 was decreased by 39%, indicating differential sensitivity of these cytokines to glucocorticoids. Endogenous corticosteroid levels increased as TNF levels decreased, supporting the contention that glucocorticoids regulate TNF synthesis. In contrast, IL-1 levels rose concurrently with corticosterone. These data indicate a sequential activation of cytokine gene expression in vivo, which may be critical to the cascade of events leading to septic shock, and provide evidence that Kupffer cells are a major source of cytokines in endotoxemia. Finally, the differential sensitivity of cytokine expression to glucocorticoids may in part explain the inadequacy of the latter in the treatment of sepsis.
...
PMID:In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. 199 64
Tumor necrosis factor
(
TNF
) induced by bacterial
lipopolysaccharide
(
LPS
) was shown to have an important role in precipitation of septic shock and disseminated intravascular clotting (DIC). At the endothelial level
TNF
down-regulates thrombomodulin (thus preventing protein C formation) and inhibits the production of tissue plasminogen activator (t-PA), thus impairing anticoagulant mechanisms. On the other hand,
TNF
up-regulates the production of procoagulant factors such as t-PA inhibitor (PAI), tissue factor and platelet activating factor (PAF). These effects create an imbalance between procoagulant and anticoagulant mechanisms, in favor of the former.
TNF
also activates polymorphonuclears (PMNs), and increases their chemotaxis and adherence to endothelial surfaces by up-regulation of specific endothelial (ELAM-1) and PMN (CDw18) adherence proteins. The damage inflicted by activated PMN to the endothelial cell promotes tissue factor exposure and PAI release, with initiation of the characteristic explosive coagulation process of DIC, facilitated by the dissociation between pro- and anticoagulant mechanisms induced by
TNF
. These newly discovered mechanisms precipitating septic shock and DIC enable consideration of new treatments for this condition as anti-
TNF
antibodies or
TNF
inhibitors, anti-ELAM-1 antibodies anti-tissue factor antibodies, administration of activated factor C, etc. These therapeutic approaches may revolutionize the treatment of septic shock and DIC in the next decade.
...
PMID:Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis: potential new therapeutic implications. 199 4
Tumor necrosis factor
(
TNF
), a protein synthesized in response to the endotoxin bacterial
lipopolysaccharide
(
LPS
), is the classical mediator of acute hemorrhagic necrosis of tumors. We have demonstrated that interleukin-1 alpha (IL-1 alpha), with a spectrum of activities very similar to those of
TNF
, also causes acute hemorrhagic necrosis of tumors. Both
TNF
and IL-1 induce a cascade of events including the synthesis or release of each other. The present studies were thus undertaken to determine whether the hemorrhagic necrosis induced in tumors by IL-1 alpha is due to
TNF
. Kinetic parameters of IL-1 alpha-induced hemorrhage were similar to those observed with recombinant murine TNF-alpha (TNF-alpha) or
LPS
in RIF-1 fibrosarcomas in C3H/HeN (endotoxin-sensitive) mice. However, the amount of
TNF
found in the sera or tumors of animals treated with
LPS
was more than 20-fold higher than in mice treated with IL-1 alpha, and
LPS
induced similar degrees of hemorrhagic necrosis, which was measured by determining the packed volume of red blood cells by 59Fe labeling. A low but significantly hemorrhagic dose of IL-1 alpha induced no detectable
TNF
in tumors. Pretreatment with 250 micrograms of neutralizing antibody to
TNF
had no effect on IL-1 alpha-induced hemorrhage, whereas TNF-alpha- and
LPS
-induced hemorrhagic effects were significantly reduced. These results demonstrate an important antitumor activity of IL-1 alpha that appears to be independent of
TNF
.
...
PMID:Acute hemorrhagic necrosis of tumors induced by interleukin-1 alpha: effects independent of tumor necrosis factor. 206 44
We investigated
lipopolysaccharide
-induced tumor necrosis factor production in vitro by peripheral blood monocytes from patients with various liver diseases.
Tumor necrosis factor
production was found to be significantly reduced in patients with chronic hepatitis B (n = 17; 135 +/- 30 pg tumor necrosis factor/ml; mean +/- S.E.M.) and patients with chronic non-A, non-B hepatitis (n = 15; 212 +/- 22 pg tumor necrosis factor/ml) compared with healthy control individuals (n = 47; 411 +/- 40 pg tumor necrosis factor/ml; p less than 0.0005 and p less than 0.01, respectively). This reduced tumor necrosis factor production was not only seen with an optimal stimulating concentration of
lipopolysaccharide
(100 ng/ml) but also with suboptimal concentrations (0.1 ng/ml). In contrast to patients with chronic viral hepatitis, monocytes from patients with alcohol-induced cirrhosis (n = 26; 444 +/- 49 pg tumor necrosis factor/ml), primary biliary cirrhosis (n = 7; 412 +/- 81 pg tumor necrosis factor/ml) and alcohol-induced fatty liver changes (n = 5; 401 +/- 62 pg tumor necrosis factor/ml) produced normal amounts of tumor necrosis factor when stimulated with an optimal concentration of
lipopolysaccharide
. Lipopolysaccharide (0.1 ng
lipopolysaccharide
/ml)-stimulated peripheral blood monocytes of patients with chronic hepatitis B (n = 15; 102 +/- 32 pg/ml) or non-A, non-B hepatitis (n = 13; 97+/- 16 pg/ml) could not be induced to produce more tumor necrosis factor either when prestimulated with gamma-interferon (170 +/- 45 pg/ml and 149 +/- 32 pg/ml, respectively), a lymphokine known to activate monocytes, or with the cyclooxygenase inhibitor indomethacin to reduce the suppressive effect of prostaglandin E2 (148 +/- 40 pg/ml and 153 +/- 45 pg/ml, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis. 212 37
Tumor necrosis factor
(
TNF
) released by
lipopolysaccharide
(
LPS
)-stimulated mononuclear phagocytes is a critical mediator of sepsis. We examined the capacities of rough mutant Salmonella typhimurium
LPS
(Rc) and
LPS
partial structures lipid A, monophosphoryl lipid A (MPLA), lipid IVA, and lipid X to induce production of
TNF
in whole blood. Rc
LPS
(0.0001-10 ng/ml) produced a dose-dependent release of
TNF
as determined by cytotoxicity of actinomycin D-sensitized L929 murine fibroblasts. Lipid A, MPLA, lipid IVA, and lipid X exhibited decreasing capacities to stimulate production of
TNF
in whole blood, respectively. Fractional deacylation of
LPS
by incubation with acyloxyacyl hydrolase isolated from human leukocytes produced a reduction in the capacity of
LPS
to induce
TNF
release in whole blood. Maximal enzymatic deacylation reduced activity of
LPS
by greater than 100-fold. Coincubation with lipid IVA inhibited
TNF
release induced by Rc
LPS
or lipid A, but not by phorbol ester. In contrast, MPLA, lipid X, and deacylated
LPS
failed to inhibit
LPS
-stimulated release of
TNF
. Corresponding to the inhibition of the release of
TNF
protein, lipid IVA also inhibited the accumulation of
TNF
mRNA in
LPS
-stimulated mononuclear cells. These results suggest that lipid IVA may act as a competitive antagonist of
LPS
, perhaps at the receptor level.
...
PMID:Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. 219 1
Tumor necrosis factor
(
TNF
) has been proposed as a primary inflammatory mediator of septic shock. In vitro and in vivo studies indicate that endotoxin- or
lipopolysaccharide
(
LPS
)-activated macrophages are a principle source of
TNF
; however, membrane signal transduction and intracellular pathways by which
LPS
triggers
TNF
production in macrophages are unclear. Recent evidence indicates that specific protein phosphorylation via activation of protein kinase C (PKC) is an early, critical step in the signaling of macrophage
TNF
production by phorbol esters. We hypothesize that PKC activation is also required in
LPS
-signaled Kupffer cell (KC)
TNF
production. Murine KCs were obtained by liver perfusion and digestion and then stimulated with
LPS
(Escherichia coli O111:B4) or
LPS
in the presence of H-7, a selective PKC inhibitor. Conditioned media was collected at 3 hr for assay of
TNF
utilizing the L929 cytolysis bioassay standardized to murine-rTNF-alpha. We found that H-7 inhibited significantly
LPS
signaled
TNF
release at a concentration of 10 microM, while H-8 (a cyclic nucleotide specific inhibitor) had no effect. The effect of H-7 was dose dependent and present at varying concentrations of
LPS
. Down regulation of PKC activity by preincubation of KCs with phorbol myristate acetate (PMA, a direct activator of PKC) also resulted in significantly reduced
TNF
release after
LPS
stimulation. The inhibitor H-7 (10 microM) also significantly inhibited
LPS
signaled prostaglandin E2 release in Kupffer cells. Total and specific intracellular protein phosphorylation was determined by trichloroacetic acid precipitation and SDS-polyacrylamide gel electrophoresis after labeling stimulated Kupffer cells with 32Pi. Total protein phosphorylation was not significantly altered by
LPS
stimulation; however, autoradiograms from PMA- and
LPS
-stimulated KCs demonstrate enhanced phosphorylation of a 40-kDa protein (2.7 +/- 0.9-fold) and a 33-kDa protein (3.1 +/- 1.0-fold) which were inhibited by H-7. We conclude that activation of PKC and protein phosphorylation are required steps in the signal transduction pathway of
LPS
-stimulated
TNF
production in Kupffer cells.
...
PMID:Tumor necrosis factor production by Kupffer cells requires protein kinase C activation. 220 49
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>